FibroBiologics, Inc. (FBLG) Income Statement
FBLG FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsFBLG revenue and net income
FBLG growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
FBLG quarterly EPS vs estimates
FibroBiologics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: October 30, 2026 (estimate $-0.63).
FBLG income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $832,000 | $573,000 | $437,000 | $94,000 | — | — |
| Gross profit | −$832,000 | −$573,000 | −$437,000 | −$94,000 | — | — |
| Research & development | $7.4M | $4.5M | $2.4M | $1.1M | $521,000 | $669,000 |
| Sales, general & admin | $9.2M | $9.2M | $6.5M | $3.3M | $1.1M | $500,000 |
| Total operating expenses | $15.8M | $13.7M | $8.9M | $4.5M | $1.6M | $1.2M |
| Operating income | −$16.6M | −$13.7M | −$8.9M | −$4.5M | −$1.6M | −$1.2M |
| Interest income | $247,000 | $251,000 | $0 | — | — | — |
| Interest expense | $204,000 | $20,000 | $147,000 | $654,000 | $4,000 | — |
| Income before taxes | −$18.6M | −$11.2M | −$16.5M | −$5.1M | −$1.6M | −$1.2M |
| Net income | −$18.6M | −$11.2M | −$16.5M | −$5.1M | −$1.6M | −$1.2M |
| EBITDA | −$17.6M | −$10.6M | −$15.9M | −$4.4M | −$1.6M | — |
| EPS (diluted) | −$5.19 | −$3.21 | $0.33 | −$3.22 | −$1.04 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $554,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $234,000 | $231,000 | $206,000 | — | $153,000 | — | $140,000 | $137,000 | $130,000 | $112,000 |
| Gross profit | — | — | −$234,000 | −$231,000 | −$206,000 | — | $277,000 | — | −$140,000 | −$137,000 | −$130,000 | −$112,000 |
| Research & development | $1.7M | $3.0M | $797,000 | $2.8M | $2.0M | $1.8M | $1.4M | $1.2M | $975,000 | $960,000 | $773,000 | $571,000 |
| Sales, general & admin | $2.4M | $2.1M | $1.8M | $2.2M | $2.4M | $2.8M | $2.4M | $2.1M | $2.2M | $2.5M | $1.7M | $1.5M |
| Total operating expenses | $4.0M | $5.1M | $2.4M | $5.0M | $4.5M | $4.5M | $3.7M | $3.4M | $3.2M | $3.5M | $2.5M | $2.1M |
| Operating income | −$4.0M | −$5.1M | −$2.6M | −$5.0M | −$4.5M | −$4.5M | −$3.7M | −$3.4M | −$3.2M | −$3.5M | −$2.5M | −$2.1M |
| Interest income | $15,000 | $20,000 | $25,000 | $73,000 | $50,000 | $99,000 | $63,000 | $79,000 | $70,000 | $39,000 | — | $0 |
| Interest expense | $7,000 | $4,000 | $204,000 | $0 | $0 | $0 | $6,000 | $5,000 | $5,000 | $4,000 | $1,000 | $0 |
| Income before taxes | −$4.1M | −$5.0M | −$3.2M | −$5.8M | −$4.7M | −$5.0M | −$3.1M | −$500,000 | $898,000 | −$8.5M | −$9.7M | −$2.2M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | — | $1 |
| Net income | −$4.1M | −$5.0M | −$3.2M | −$5.8M | −$4.7M | −$5.0M | −$3.1M | −$500,000 | $898,000 | −$8.5M | −$9.7M | −$2.2M |
| EBITDA | −$3.9M | −$4.8M | −$2.8M | −$5.5M | −$4.5M | −$4.8M | −$2.9M | −$352,000 | $1.0M | −$8.3M | −$9.6M | −$2.1M |
| EPS (diluted) | −$0.66 | −$1.33 | −$0.60 | −$2.60 | −$0.12 | −$2.80 | −$0.09 | −$0.20 | $0.60 | −$0.27 | — | — |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −670.0% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −559.4% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in FBLG's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
FBLG financial results
FibroBiologics reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $18.6 million. Diluted earnings per share came to −$5.19.
See the FBLG stock overview for the latest quote and news, or the FBLG chart for price history and technical indicators.
FBLG income statement FAQ
Does FibroBiologics have revenue?
FibroBiologics reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is FibroBiologics profitable?
No. FibroBiologics reported a net loss of $18.6 million in fiscal 2026.
How much does FibroBiologics spend on research and development?
FibroBiologics spent $7.4 million on research and development in fiscal 2026.
What are FibroBiologics's earnings per share?
FibroBiologics earned $-5.19 per diluted share in fiscal 2026, compared with $-3.21 a year earlier.
When will FibroBiologics report its next earnings?
FibroBiologics is expected to report results for the quarter ending September 30, 2026 on October 30, 2026.
When does FibroBiologics's fiscal year end?
FibroBiologics's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on February 24, 2026.